Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERT-IJS vs EU-Perjeta with trastuzumab and chemotherapy as neoadjuvant treatment in HR-negative HER2-positive early or locally advanced breast cancer
2023-506163-34-00Phase 3Completed
- Sponsor
- Mylan
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised trial of PERT-IJS in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Mylan. Started Nov 2023; status: completed.
02
Drugs
PERT-IJS
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2023-506163-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506163-34-00.